Building Biobetters :The regulatory landscape

Regardless of whether new forms of presently promoted, or again organic medications, biobetters are items particularly intended to amplify clinical execution. Execution advancement may incorporate, among different upgrades, improved focusing on and conveyance, expanded action and half-life, and diminished immunogenicity. Along these lines, it is important that such items are created productively and rapidly, to permit patients access to drugs that give greatest clinical advantages.

  • Clinical Strategies for Biosimilar & Bio superior Development Programs
  • Product Similarity for Biosimilars & Analytical Challenges
  • Manufacturing of Complex Biobetters: Half-Life Extended Fusion Proteins and Bispecific Molecules
  • Developing Biobetters with Improved Efficacy and Safety by Addressing Product Immunogenicity with Tolerogenic Nanoparticles
  • Why BioDifferent Equals BioBetter
  • Blood Brain targeting of therapeutic lysosomal enzymes
  • Comparability in Biosimilar Development
  • Clinical approach to biosimilar development
  • Novel Approaches in drug discovery

Related Conference of Building Biobetters :The regulatory landscape

Building Biobetters :The regulatory landscape Conference Speakers